Print Page | Close Window

Cytokinetics, Inc. (NASDAQ: CYTK) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and other medical conditions.  Cytokinetics currently has three compounds in clinical development: omecamtiv mecarbil in Phase II for acute and chronic heart f Details >>

Link to Annual Report & Stockholder Meeting Materials and Information

Stock Quote
CYTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.08 (1.81%)
Market Cap$158,883,060
Shares Outstanding36,609,000
Data as of 07/22/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsDetails >>
07/16/14Cytokinetics to Announce Second Quarter Results on July 30, 2014Printer Friendly Version
07/10/14Cytokinetics Announced Additional Results Relating to Tirasemtiv from Pre-Specificed Subgroup Analyses of BENEFIT-ALSPrinter Friendly Version
07/03/14Cytokinetics Announces Additional Data from BENEFIT-ALS to be Presented at the 13th International Congress on Neuromuscular DiseasesPrinter Friendly Version
06/13/14Cytokinetics Announces Data Relating to Tirasemtiv Presented at the 2014 Annual Spinal Muscular Atrophy ConferencePrinter Friendly Version
Upcoming EventsDetails >>
07/30/14 4:30 p.m. ET
Q2 2014 Cytokinetics, Inc. Earnings Conference Call
Featured ReportDetails >>
Download Documentation 2010 Annual Report

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.